Table 2.
Univariate analysis of prognostic factors for overall survival and progression-free survival.
| Variables | OS | PFS | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Gender | ||||
| Male | 1 | 1 | ||
| Female | 0.879 (0.604, 1.279) | 0.500 | 0.941 (0.667, 1.328) | 0.731 |
| Age (years) | 0.995 (0.983, 1.007) | 0.380 | 0.994 (0.983, 1.005) | 0.278 |
| BCLC classs | ||||
| C | 1 | 1 | ||
| B | 0.491 (0.352, 0.686) | 0.000 | 0.572 (0.416, 0.786) | 0.001 |
| A | 0.266 (0.183, 0.386) | 0.000 | 0.487 (0.355, 0.666) | 0.000 |
| Hepatitis | ||||
| Hepatitis B | 1 | 1 | ||
| Other | 0.926 (0.669, 1.283) | 0.646 | 1.037 (0.773, 1.391) | 0.809 |
| Child-pugh score | ||||
| A | 1 | |||
| B | 1.019 (0.704, 1.475) | 0.920 | 1.073 (0.766, 1.503) | 0.683 |
| TB (µmol/L) | 1.004 (0.995, 1.013) | 0.353 | 1.005 (0.997, 1.014) | 0.234 |
| Albumin (g/L) | 0.989 (0.969, 1.009) | 0.261 | 1.001 (0.981, 1.022) | 0.905 |
| PT (s) | 0.988 (0.902, 1.083) | 0.801 | 0.969 (0.890, 1.056) | 0.476 |
| AST (μmol/L) | 1.002 (1.001, 1.003) | 0.002 | 1.001 (1.000, 1.002) | 0.007 |
| ALT (μmol/L) | 1.000 (0.999, 1.002) | 0.728 | 1.001 (1.000, 1.002) | 0.198 |
| PLR | 1.003 (1.002, 1.004) | 0.000 | 1.002 (1.001, 1.004) | 0.001 |
| NLR | 1.032 (1.017, 1.046) | 0.000 | 1.022 (1.007, 1.037) | 0.005 |
| Tumor size | 1.067 (1.036, 1.099) | 0.000 | 1.058 (1.030, 1.088) | 0.000 |
| Tumor number | ||||
| >3 | 1 | 1 | ||
| ≤3 | 0.846 (0.270, 2.649) | 0.774 | 0.932 (0.298, 2.917) | 0.903 |
| α-Fetoprotein level | ||||
| ≥400 ng/mL | 1 | 1 | ||
| <400 ng/ml | 0.958 (0.726, 1.265) | 0.764 | 0.950 (0.734, 1.229) | 0.695 |
| Ascites | ||||
| Present | 1 | 1 | ||
| Absent | 0.923 (0.624, 1.366) | 0.688 | 0.990 (0.688, 1.424) | 0.955 |
| TACE sessions | 0.701 (0.646, 0.761) | 0.000 | 0.889 (0.835, 0.946) | 0.000 |
| Treatment method | ||||
| D-TACE + Liopodol | 1 | 1 | ||
| D-TACE | 1.610 (1.003, 2.583) | 0.049 | 1.323 (0.866, 2.019) | 0.195 |
Note. OS: overall survival; PFS: progression-free survival; HR: hazard ratio; CI: confidence interval; SD: standard deviation; BCLC: barcelona clinical liver cancer; TB: total bilirubin; PT: prothrombin time; AST: aspartate aminotransferase; ALT: alanine aminotransferase; PLR: platelet-to-lymphocyte ratio; NLR: neutrophil-to-lymphocyte ratio; D-TACE: drug-elutingbeads-transcatheter arterial chemoembolization.